The Therapeutic Goods Administration (TGA) is aware that some European countries have paused vaccination with the AstraZeneca ChAdOx1-S COVID-19 vaccine after reports of blood clots following vaccination.
The TGA advises that a link between blood clots and the AstraZeneca vaccine has not been confirmed. To 11 March 2021, the TGA has received no reports of blood clots following use of the AstraZeneca ChAdOx1-S vaccine in Australia. Extensive international experience does not indicate an increased risk of blood clots associated with the vaccine. Blood clots can occur naturally and are not uncommon.
Denmark, Iceland and Norway have temporarily ceased vaccination with the AstraZeneca ChAdOx1-S COVID-19 vaccine as a precautionary measure in response to a number of reports of blood clots following administration of the vaccine, including one case in Denmark where a person died. The European Medicines Agency’s safety committee is conducting a rapid review of the issue.
Vaccination programs with the AstraZeneca vaccine are continuing in other countries, including the United Kingdom (UK) and France. The UK is encouraging people to continue to be vaccinated.
Blood clots are considered ‘adverse events of special interest’, which are closely monitored in Australia and by overseas regulators.
The TGA works closely with international regulators and shares information about COVID-19 vaccine safety. If we detect a safety concern, we will take rapid action to address it and provide information to the public.
Consumers and health professionals are encouraged to report problems with medicines or vaccines. Your report will contribute to the TGA’s monitoring of these products.
The TGA cannot give advice about an individual’s medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse event associated with a medicine or vaccine.